title: Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
abstract: Neuroblastomas (NBL) and Ewing's sarcomas (EWS) together cause 18% of all pediatric cancer deaths. Though there is growing interest in targeting the dysregulated metabolism of cancer as a therapeutic strategy, this approach has not been fully examined in NBL and EWS. In this study, we first tested a panel of metabolic inhibitors and identified the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) as the most potent chemotherapeutic across all NBL and EWS cell lines tested. Myc, a master regulator of metabolism, is commonly overexpressed in both of these pediatric malignancies and recent studies have established that Myc causes cancer cells to become "addicted" to glutamine. We found DON strongly inhibited tumor growth of multiple tumor lines in mouse xenograft models. In vitro, inhibition of caspases partially reversed the effects of DON in high Myc expressing cell lines, but not in low Myc expressing lines. We further showed that induction of apoptosis by DON in Myc-overexpressing cancers is via the pro-apoptotic factor Bax. To relieve inhibition of Bax, we tested DON in combination with the Bcl-2 family antagonist navitoclax (ABT-263). In vitro, this combination caused an increase in DON activity across the entire panel of cell lines tested, with synergistic effects in two of the N-Myc amplified neuroblastoma cell lines. Our study supports targeting glutamine metabolism to treat Myc overexpressing cancers, such as NBL and EWS, particularly in combination with Bcl-2 family antagonists.
authors.affiliation: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
authors.forename: Rachelle R
authors.initials: RR
authors.lastname: Olsen
authors.affiliation: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
authors.forename: Michelle N
authors.initials: MN
authors.lastname: Mary-Sinclair
authors.affiliation: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
authors.forename: Zhirong
authors.initials: Z
authors.lastname: Yin
authors.affiliation: Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Freeman
mesh_terms: D000814:Aniline Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000494:pharmacology; D017209:Apoptosis; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D020169:Caspases / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003980:Diazooxonorleucine / Q000008:administration & dosage* / Q000494:pharmacology; D004357:Drug Synergism; D005973:Glutamine / Q000037:antagonists & inhibitors*; D006801:Humans; D051379:Mice; D009447:Neuroblastoma / Q000188:drug therapy* / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000378:metabolism; D013449:Sulfonamides / Q000008:administration & dosage* / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
chemical_list: D000814:Aniline Compounds; D000964:Antimetabolites, Antineoplastic; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D013449:Sulfonamides; D003980:Diazooxonorleucine; D005973:Glutamine; D020169:Caspases; C528561:navitoclax